Takeda Signs a Licensing Agreement with Curadev for Stimulator of Interferon Genes (STING) Agonist
Shots:
- Takeda enters into a licensing agreement with Curadev for its Stimulator of Interferon Genes (STING) agonist/ CRD5500 and its associated patents
- The focus of the agreement is to develop immuno-oncology targets- providing one day deliver transformational benefit to patients. Additionally- out-licenses its IP portfolio to Endo- Medivation & Roche
- Curadev’s CRD5500 is a sting agonist amenable to bioconjugation as an ADC targeting anti-PD-L1/anti-CTLA4/IDO-TDOi- activating human STING variants to shrink tumors and successfully conjugated with trastuzumab
Ref: PRNewsWire | Image:Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com